Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brontictuzumab

X
Drug Profile

Brontictuzumab

Alternative Names: Anti-Notch 1; Anti-Notch 1 monoclonal antibody; OMP-52M51

Latest Information Update: 02 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Developer OncoMed Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Notch-1 receptor antagonists; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Adenoid cystic carcinoma; Colorectal cancer; Solid tumours
  • Discontinued Haematological malignancies

Most Recent Events

  • 28 Feb 2020 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 24 Apr 2019 OncoMed Pharmaceuticals has been acquired by Mereo BioPharma
  • 28 Jan 2019 No recent reports of development identified for clinical-Phase-Unknown development in Adenoid-cystic-carcinoma in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top